Therapeutic Potential of the Dual Peroxisome Proliferator Activated Receptor (PPAR)/ Agonist Aleglitazar in Attenuating TNF-mediated Inflammation and Insulin Resistance in Human Adipocytes: A Review
Published: 2019-12-10
Page: 34-44
Issue: 2019 - Volume 2 [Issue 1]
Naser A. ElSawy *
Department of Anatomy and Embryology, Faculty of Medicine, Zagazig University, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Aleglitazar, is a novel promising drug, that related to peroxisome proliferator-activated receptor (PPARα&γ) agonists which shows an ant-diabetic and anti-inflammatory characteristics. The goal of this study is to evaluate anti-inflammatory and anti-arthritic properties of Aleglitazar in arthritis models induced in experimental animals and to conclude the comparative ulcerogenic potential of diclofenac in type 2 diabetes animals. The anti-inflammatory characteristics of Aleglitazar will be investigated in Carrageenan-induced hind paw edema as acute inflammation.
The Aim of the review: This study aims to assess anti-inflammatory and anti-arthritic activities of aleglitazar in arthritis models induced in experimental animals. It is to determine comparative ulcerogenic potential diclofenac in type 2 diabetic animals on gastric mucosa in rats.
Keywords: PPAR, Aleglitazar, TNF, inflammation insulin resistance, adipocytes.